Prognostic factors for treatment failure of imiquimod treatment in basal cell carcinoma – an observational study
Corresponding Author
B.J.A. Verkouteren
Department of Dermatology, Maastricht University Medical Centre, Maastricht, The Netherlands
GROW Research Institute for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands
Share first authorship.*Correspondence: B.J.A. Verkouteren. E-mail: [email protected]
Search for more papers by this authorL.C.F. Oostewechel
Department of Dermatology, Maastricht University Medical Centre, Maastricht, The Netherlands
Share first authorship.Search for more papers by this authorP.J. Nelemans
Department of Epidemiology, Maastricht University Medical Centre, Maastricht, The Netherlands
Search for more papers by this authorK.A.E. Sinx
Department of Dermatology, Maastricht University Medical Centre, Maastricht, The Netherlands
GROW Research Institute for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands
Search for more papers by this authorA.H.M.M. Arits
Department of Dermatology, Maastricht University Medical Centre, Maastricht, The Netherlands
Department of Dermatology, Catherina Hospital, Eindhoven, The Netherlands
Search for more papers by this authorA.I.P. Vernemmen
Department of Pathology, Maastricht University, Maastricht, The Netherlands
Search for more papers by this authorV.J.L. Winnepenninckx
Department of Pathology, Maastricht University, Maastricht, The Netherlands
Search for more papers by this authorN.W.J. Kelleners-Smeets
Department of Dermatology, Maastricht University Medical Centre, Maastricht, The Netherlands
GROW Research Institute for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands
Search for more papers by this authorK. Mosterd
Department of Dermatology, Maastricht University Medical Centre, Maastricht, The Netherlands
GROW Research Institute for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands
Search for more papers by this authorCorresponding Author
B.J.A. Verkouteren
Department of Dermatology, Maastricht University Medical Centre, Maastricht, The Netherlands
GROW Research Institute for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands
Share first authorship.*Correspondence: B.J.A. Verkouteren. E-mail: [email protected]
Search for more papers by this authorL.C.F. Oostewechel
Department of Dermatology, Maastricht University Medical Centre, Maastricht, The Netherlands
Share first authorship.Search for more papers by this authorP.J. Nelemans
Department of Epidemiology, Maastricht University Medical Centre, Maastricht, The Netherlands
Search for more papers by this authorK.A.E. Sinx
Department of Dermatology, Maastricht University Medical Centre, Maastricht, The Netherlands
GROW Research Institute for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands
Search for more papers by this authorA.H.M.M. Arits
Department of Dermatology, Maastricht University Medical Centre, Maastricht, The Netherlands
Department of Dermatology, Catherina Hospital, Eindhoven, The Netherlands
Search for more papers by this authorA.I.P. Vernemmen
Department of Pathology, Maastricht University, Maastricht, The Netherlands
Search for more papers by this authorV.J.L. Winnepenninckx
Department of Pathology, Maastricht University, Maastricht, The Netherlands
Search for more papers by this authorN.W.J. Kelleners-Smeets
Department of Dermatology, Maastricht University Medical Centre, Maastricht, The Netherlands
GROW Research Institute for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands
Search for more papers by this authorK. Mosterd
Department of Dermatology, Maastricht University Medical Centre, Maastricht, The Netherlands
GROW Research Institute for Oncology and Developmental Biology, Maastricht University, Maastricht, The Netherlands
Search for more papers by this authorConflict of interest
None declared.
Open Research
Data availability statement
Data are available upon reasonable request.
References
- 1Jansen MHE, Mosterd K, Arits A et al. Five-year results of a randomized controlled trial comparing effectiveness of photodynamic therapy, topical imiquimod, and topical 5-fluorouracil in patients with superficial basal cell carcinoma. J Invest Dermatol 2018; 138: 527–533.
- 2Williams HC, Bath-Hextall F, Ozolins M et al. Surgery versus 5% imiquimod for nodular and superficial basal cell carcinoma: 5-year results of the SINS randomized controlled trial. J Invest Dermatol 2017; 137: 614–619.
- 3Geisse J, Caro I, Lindholm J et al. Imiquimod 5% cream for the treatment of superficial basal cell carcinoma: results from two phase III, randomized, vehicle-controlled studies. J Am Acad Dermatol 2004; 50: 722–733.
- 4Shumack S, Robinson J, Kossard S et al. Efficacy of topical 5% imiquimod cream for the treatment of nodular basal cell carcinoma: comparison of dosing regimens. Arch Dermatol 2002; 138: 1165–1171.
- 5Klein SL, Morgan R. The impact of sex and gender on immunotherapy outcomes. Biol Sex Differ 2020; 11: 24.
- 6Sinx KAE, Nelemans PJ, Kelleners-Smeets NWJ et al. Surgery versus combined treatment with curettage and imiquimod for nodular basal cell carcinoma (SCIN): 1-year results of a non-inferiority, randomized controlled trial. J Am Acad Dermatol 2020; 83: 469.
- 7Arits AH, Mosterd K, Essers BA et al. Photodynamic therapy versus topical imiquimod versus topical fluorouracil for treatment of superficial basal-cell carcinoma: a single blind, non-inferiority, randomised controlled trial. Lancet Oncol 2013; 14(7): 647–654.
